Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies.

摘要: Fucoidan is a sulfated polysaccharide extracted from brown seaweeds. Studies have shown that fucoidan has curative effects on the chronic renal failure, acute kidney injury, and diabetic nephropathy both in vitro vivo. Saccharina japonica most economically important seaweed cultivated China consumed as marine vegetable East Asia. Over past thousand years, Chinese people traditionally used this plant to cure edema, symptom of diseases. The composed primarily fucose galactose with smaller amounts other monosaccharides. Structure-activity relationship studies reveal molecular weight, monosaccharide compositions, sulfation degree positions sulfates influences renoprotective activity. Low weight exhibits better activity than fucoidan. Pharmacological indicate inhibits fibrosis glomerular sclerosis by reducing accumulation extracellular matrix. In addition, reduces inflammatory response P-selectin expression, maintains basement membrane structural integrity, improves filtration function, protects glycosaminoglycans abnormal degradation. effective constituent Haikun Shenxi capsule (HSC) japonica. HSC was approved for treating diseases Food Drug Administration 2003. Based results peer-reviewed publications, we will recapitulate structure, pharmacology, reported clinical cases, efficacy, future perspectives HSC. This review summarize knowledge gained stimulate in-depth academic world widely.